An interventional study of cognitive rehabilitation program in Parkinson Disease (PD), sponsored by University Hospital, Clermont-Ferrand. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Parkinson Disease by University Hospital, Clermont-Ferrand — 5 open to participants now, 5 under way, none of them phase 3. Parkinson Disease · University Hospital, Clermont-Ferrand.
Among the 25 studies in Parkinson Disease by University Hospital, Clermont-Ferrand, this one is the 18th largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2026, is one of 18 with no phase, and was the 25th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →5 of the 25 studies in Parkinson Disease by University Hospital, Clermont-Ferrand are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
University Hospital, Clermont-Ferrand · Sites in France
Ages 18–75 · Healthy volunteers
University Hospital, Clermont-Ferrand · Sites in France
Ages 18–90
University Hospital, Clermont-Ferrand · Sites in France
Ages 18–80
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 46 across the 23 interventional studies, 250 across the 2 observational. Of the 14 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 177 are open to participants now.
2 of the studies in Parkinson Disease by University Hospital, Clermont-Ferrand that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07702266University Hospital, Clermont-FerrandPrimary Parkinsonian Pain: Clinical Association and Phenotype | 2027-09-30 |
| NCT07813156University Hospital, Clermont-FerrandIdiopathic Parkinson's Disease: Interest of an Early Group-Based Cognitive Rehabilitation Program (LIFECOG-PD) | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 25 studies in Parkinson Disease by University Hospital, Clermont-Ferrand, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Current pharmacological treatments have not demonstrated significant improvement in cognitive impairment in Parkinson's disease (PD). Given the high prevalence and serious impact of cognitive impairment in PD, there is a pressing need for non-pharmacological interventions with demonstrated functional benefits. Cognitive rehabilitation is a structured program designed to help improve or compensate for patients' cognitive abilities by providing an approach tailored to each patient's individual needs and goals. Neuropsychologists from French Parkinson's Disease expert centers have developed a new cognitive rehabilitation program called LifeCOG-PD, for PD patients with a subjective cognitive complaint or a mild cognitive impairment (MCI), delivered at the hospital in seven 90-minute sessions conducted in groups of 3-4 participants. This program, combining psychoeducation, practical strategies, and personalized goal setting, aims to maintain patients' daily autonomy, enhance quality of life, and delay the cognitive impact of the disease.
By evaluating feasibility, acceptability and functional outcomes, this study will contribute critical data to inform future PD management guidelines to help support autonomy and cognitive resilience in PD.
This pilot interventional therapeutic study will aim at evaluating the feasibility and acceptability of a new cognitive rehabilitation program designed to preserve autonomy and social roles among early PD MCI patients or isolated subjective cognitive complaint.
24 patients will be enrolled in this study in 5 french centers : Clermont-Ferrand, Bordeaux, Créteil, Nancy and Strasbourg.
The inclusion period is 12 months, and each patient's participation duration is a maximum of 13 months. This study will include 10 visits at the hospital :
Patients will receive 7 sessions of 1.5 hours each at their expert centre, spaced 15 days apart, in groups of 3-4 patients. The sessions will address theoretical and practical topics such as working memory and executive functions, attention, and prospective memory in relation to their personal goals. The neuropsychologist will be blinded from the neuropsychological assessment and the functional goals.
If the patient has a caregiver (spouse or other relative), the investigator may propose them to participate in the study. Their participation will consist of completing a satisfaction questionnaire assessing the perceived benefits of the program for the patient at 3 and 9 months post-program. If they agree, the investigator will obtain their agreement to the collection and use of their data within the framework of this research.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Men or women ≥18 years old, diagnosed with idiopathic Parkinson's disease according to the official diagnostic criteria defined by the Movement Disorder Society (MDS) ;
Exclusion Criteria:
Any associated neurological disorder or active psychiatric pathology, including severe depressive episode or active psychotic episode. Participants with a Beck Depression Inventory (BDI-II) score above 21 will be excluded from the study and referred to an appropriate healthcare professional for further evaluation and follow-up as needed.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive the new cognitive rehabilitation program.
Other: cognitive rehabilitation program
Patients will receive the program in 7 sessions of 1.5 hours each at their expert centre, spaced 15 days apart, in groups of 3-4 patients. The sessions will address theoretical and practical topics such as working memory and executive functions, attention, and prospective memory in relation to their personal goals.
Proportion of patients completing the 7 sessions of the program
Time frame: at the end of the program at 12 weeks
Proportion of ineligible participants after screening and inclusion
Time frame: at inclusion visit
Number of participants who withdrew until the end of the program (Dropout rates).
Time frame: at the end of the program at 12 weeks
Perceived level of interest with a satisfaction questionnaire (The Satisfaction with Therapy and Therapist Scale-Revised (STTS-R)
Time frame: At the end the program at 12 weeks
Participants' experience of the program (practical organization of the sessions, understanding and expectations, overall acceptability and recommendations) using qualitative questionnaire
Time frame: et the end of the program at 12 weeks
Perceived benefits of the program as reported by the participant at 3 months post treatment using qualitative questionnaire
Time frame: at 24 weeks
Perceived benefits of the program as reported by the participant at 9 months post treatment using qualitative questionnaire
Time frame: at 48 weeks
Perceived benefits of the program as reported by one of the patient's relatives at 3 months post treatment using qualitative questionnaire
Time frame: at 24 weeks
Perceived benefits of the program as reported by one of the patient's relatives at 9 months post treatment using qualitative questionnaire
Time frame: at 48 weeks
Level of achievement of individualized functional goals, assessed using GAS (treated as continuous data transformed by the zscore approach)
Time frame: at 24 weeks
Level of achievement of individualized functional goals, assessed using GAS (treated as continuous data transformed by the zscore approach)
Time frame: at 48 weeks
Functional autonomy with the Penn's Parkinson Autonomy Questionnaire-15 items (PDAQ-15)
Time frame: at inclusion visit
Functional autonomy with the Penn's Parkinson Autonomy Questionnaire-15 items (PDAQ-15)
Time frame: at 24 weeks
Functional autonomy with the Penn's Parkinson Autonomy Questionnaire-15 items (PDAQ-15)
Time frame: at 48 weeks
Global subjective cognitive complaints : Subjective Cognitive Complaints Questionnaire for Parkinson's disease (SCCQ-PD)
Time frame: at inclusion visit
Global subjective cognitive complaints : Subjective Cognitive Complaints Questionnaire for Parkinson's disease (SCCQ-PD)
Time frame: at 24 weeks
Global subjective cognitive complaints : Subjective Cognitive Complaints Questionnaire for Parkinson's disease (SCCQ-PD)
Time frame: at 48 weeks
Quality of life using the Parkinson's Disease Questionnaire (PDQ-39)
Time frame: at inclusion visit
Quality of life using the Parkinson's Disease Questionnaire (PDQ-39)
Time frame: at 24 weeks
Quality of life using the Parkinson's Disease Questionnaire (PDQ-39)
Time frame: at 48 weeks
Self-Esteem using the Rosenberg Self-Esteem Scale
Time frame: at inclusion visit
Self-Esteem using the Rosenberg Self-Esteem Scale
Time frame: at 24 weeks
Self-Esteem using the Rosenberg Self-Esteem Scale
Time frame: at 48 weeks
Depressive symptoms using the Beck Depression Inventory II (BDI-II)
Time frame: at inclusion visit
Depressive symptoms using the Beck Depression Inventory II (BDI-II)
Time frame: at 24 weeks
Depressive symptoms using the Beck Depression Inventory II (BDI-II)
Time frame: at 48 weeks
Global cognitive assessment using the Montreal Cognitive Assessment
Time frame: at inclusion visit
Global cognitive assessment using the Montreal Cognitive Assessment
Time frame: at 48 weeks
Episodic memory using the 16-items Free and Cued Selective Reminding Test
Time frame: at inclusion visit
Episodic memory using the 16-items Free and Cued Selective Reminding Test
Time frame: at 48 weeks
Episodic memory using the Brief Visuospatial Memory Test-R
Time frame: at inclusion visit
Episodic memory using brief Visuospatial Memory Test-R
Time frame: at 48 weeks
Attention using Digit Symbol Modalities test
Time frame: at inclusion visit
Attention using Digit Symbol Modalities test
Time frame: at 48 weeks
Attention using the Digit Span (Forward and Backward)
Time frame: at inclusion visit
Attention using digit Span (Forward and Backward)
Time frame: at 48 weeks
Executive functions using oral Letter-Number Sequencing task
Time frame: at inclusion visit
Executive functions using oral Letter-Number Sequencing task
Time frame: at 48 weeks
Executive functions using stroop Color and Word Test D-KEFS
Time frame: at inclusion visit
Executive functions using stroop Color and Word Test D-KEFS
Time frame: at 48 weeks
Visuo spatial treatment using the Benton Judgment of Line Orientation Test
Time frame: at inclusion visit
Visuo spatial treatment using the Benton Judgment of Line Orientation Test
Time frame: at 48 weeks
Visuo spatial treatment using the clock drawing test
Time frame: at inclusion visit
Visuo spatial treatment using the clock drawing test
Time frame: at 48 weeks
Language using the Boston Naming Test (French short form)
Time frame: at inclusion visit
Language using the Boston Naming Test (French short form)
Time frame: at 48 weeks
Participants' experience of the program (practical organization of the sessions, understanding and expectations, overall acceptability and recommendations) using a qualitative questionnaire
at the end of the first session of the program
Time frame: at week 0
Participants' experience of the program (practical organization of the sessions, understanding and expectations, overall acceptability and recommendations) using a qualitative questionnaire
at the end of the session 2 of the program
Time frame: at 2 weeks
Participants' experience of the program (practical organization of the sessions, understanding and expectations, overall acceptability and recommendations) using a qualitative questionnaire
at the end of the session 3 of the program
Time frame: at 4 weeks
Participants' experience of the program (practical organization of the sessions, understanding and expectations, overall acceptability and recommendations) using a qualitative questionnaire
at the end of the session 4 of the program
Time frame: at 6 weeks
Participants' experience of the program (practical organization of the sessions, understanding and expectations, overall acceptability and recommendations) using a qualitative questionnaire
at the end of the session 5 of the program
Time frame: at 8 weeks
Participants' experience of the program (practical organization of the sessions, understanding and expectations, overall acceptability and recommendations) using a qualitative questionnaire
at the end of the session 6 of the program
Time frame: at 10 weeks
Participants' experience of the program (practical organization of the sessions, understanding and expectations, overall acceptability and recommendations) using a qualitative questionnaire
at the end of the session 7 of the program
Time frame: at 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 12 months is below that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Clermont-Ferrand →